

# Investigating red blood cells of sickle cell patients who started therapy.

No registrations found.

<b>Ethical review</b>	Positive opinion
<b>Status</b>	Pending
<b>Health condition type</b>	-
<b>Study type</b>	Observational non invasive

## Summary

### ID

NL-OMON24314

### Source

NTR

### Brief title

SickleCellScreen

### Health condition

sickle cell anemia

HbSS

HbSC

Sikkelcelziekte

## Sponsors and support

**Primary sponsor:** University Medical Center Utrecht

**Source(s) of monetary or material Support:** RR Mechatronics

## Intervention

## Outcome measures

### Primary outcome

Red blood cell deformability

## Secondary outcome

Changes in red blood cell deformability over time and correlations with other laboratory parameters and clinical symptoms and signs.

## Study description

### Background summary

Sickle cell disease (SCD) is a hemoglobinopathy in which a single nucleotide mutation in the beta-globin chain causes the formation of the abnormal hemoglobin S (HbS). When HbS becomes deoxygenated it polymerises, resulting in sickling of red blood cells (RBCs). These sickled RBCs have strongly reduced deformability, leading to vaso-occlusive crises, multi organ failure and chronic hemolytic anemia.

Hydroxyurea is the only approved drug for the treatment of sickle cell disease. It increases the production of fetal hemoglobin (HbF), thereby lowering HbS levels and, consequently, decreases sickling events. There is however no accurate measurement of a dose-and-effect relation, other than the next life-threatening crisis. There also is no all-inclusive surrogate end-point to estimate disease severity.

Altered red blood cell (RBC) deformability is a feature of many RBC disorders, including SCD. It can be measured using the Lorrca (Laser-assisted Optical Rotational Red Cell Analyzer) under varying circumstances. For instance, the hypoxia-hyperoxia ektacytometry module of the Lorrca enables the measurement of RBC deformability in response to changes in oxygen tension. This is particularly relevant in the field of SCD. Variables known to be of influence for sickling (e.g. HbF levels, presence of transfusion blood) can be studied by using one single fully automated, operator independent test. We hypothesize that this single test can determine an individual's status and/or susceptibility to sickling, and measure the effect of hydroxyurea therapy.

### Study objective

Red blood cell deformability improves after start of therapy with Hydroxyurea.

### Study design

baseline, after 1, 3 and 6 months.

### Intervention

Not applicable

## Contacts

### **Public**

Laboratory for Haematology and Clinical Chemistry, UMC Utrecht

M.A.E. Rab  
Heidelberglaan 100

Utrecht 3508 GA  
The Netherlands

### **Scientific**

Laboratory for Haematology and Clinical Chemistry, UMC Utrecht

M.A.E. Rab  
Heidelberglaan 100

Utrecht 3508 GA  
The Netherlands

## Eligibility criteria

### **Inclusion criteria**

1. No blood transfusion within the past 2 months
2. Diagnosed with sickle cell anemia (HbSS, HbSC or HbS/beta-thal)
3. Starting with Hydroxyurea therapy
4. Parents/legal guardians (and child, depending on age) or adult patients must give informed consent

### **Exclusion criteria**

1. Blood transfusion within past 2 months
2. Body weight below 10 kg
3. Age <1 year

## Study design

### Design

Study type: Observational non invasive

Intervention model: Other

**Control:** N/A , unknown

### Recruitment

NL

Recruitment status: Pending

Start date (anticipated): 01-11-2017

Enrollment: 20

Type: Anticipated

## Ethics review

Positive opinion

Date: 26-10-2017

Application type: First submission

## Study registrations

### Followed up by the following (possibly more current) registration

ID: 54704

Bron: ToetsingOnline

Titel:

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

**Register**

NTR-new

NTR-old

CCMO

OMON

**ID**

NL6015

NTR6779

NL62011.041.17

NL-OMON54704

**Study results**